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Pre-treatment of human neutrophils with rGM-CSF resulted in a 3-fold increase in the rate of fMet-Leu-Phe stimulated 
reactive oxidant generation, as assessed by luminol- and lucigenin-chemiluminescence andC& secretion. When blood- 
stream neutrophils were incubated in RPM1 1640 medium supplemented with P5S]methionine, both fMet-Leu-Phe (0.1 
FM) and y-interferon (100 U/ml) stimulated a 3--4-fold increased incorporation of label into TCA-precipitable material. 
Similarly, rGM-CSF (50 U/ml) also stimulated protein biosynthesis in bloodstream neutrophils, and newly labelled poly- 
peptides were separated by two-dimensional poiyacrylamide gel electrophoresis. Two classes of polypeptides were visual- 
ised on these gels: the relative rate of labelling of one class changed very little upon rGM-CSF treatment whereas the 
relative rate of labelling of a second group increased 3312-fold. 
Neutrophil; Granulocyte-macrophage colony-stimulating factor; Protein biosynthesis 
1. INTRODUCTION 
Polymorphonuclear leukocytes (neutrophils) 
play a crucial role in the protection of the host 
against microbial pathogens and hence possess a 
wide range of cytotoxic enzymes and associated 
pathways in order to fulfill this defensive function. 
Since the early observation ]I] that neutrophils 
isolated from the bloodstream of patients with 
acute bacterial infections are functionally 
modified, there has been a growing interest in the 
mechanisms by which pathogen- or host-derived 
components can affect the bactericidal activity of 
these cells. Thus, in vitro and presumably in vivo, 
bloodstream neutrophils can be ‘primed’ into a 
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state of enhanced functional responsiveness upon 
exposure to some cytokines and other components 
which are generated during an inflammatory 
response [2], so that their capacity to respond to a 
pathogenic challenge is greatly increased. Func- 
tional changes induced by exposure to ‘priming’ 
agents include modified chemotaxis, increased oxi- 
dant generation, up-regulation of some membrane 
receptors, and enhanced phagocytosis and killing. 
We have previously shown that ‘priming’ of 
bloodstream neutrophils with either low concen- 
trations of the chemotactic peptide, met-Leu-Phe 
[3] or y-interferon [4,5], results in a transition to 
an enhanced functional state and that this is ac- 
companied by a 3-4-fold increase in the rate of 
[35S]methionine incorporation into proteins. This 
latter phenomenon was neither due to monocyte 
contamination of the neutrophil suspensions nor 
due to changes in the intracellular pool size of 
[35S]methionine, but was prevented by inhibitors 
of transcription and translation. Analysis of two- 
dimensional gels revealed two classes of newly 
labelled polypeptides, one whose rate of labelling 
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changed very little (I-2-fold) and another whose 
rate of labelling increased lo-20-fold. We have 
proposed that these, as yet unidentified, up- 
regulated proteins play a crucial role in neutrophil 
function during an inflammatory response. 
Granulocyte-macrophage colony-stimulating 
factor (GM-CSF) is a 22 kDa glycoprotein pro- 
duced by activated T cells, endothelial cells, 
fibroblasts and macrophages [6-81. It is capable of 
promoting increased proliferation of cells of the 
erythroid and myelomonocytic cell lineages, and 
can also induce ‘priming’ of mature, bloodstream 
neutrophils (see [9] for a review). The aim of the 
present work, therefore, was to determine whether 
in common with some other neutrophil ‘priming’ 
agents [3,5] rGM-CSF was also capable of ac- 
tivating de novo protein biosynthesis in circulating 
human neutrophils. 
2. MATERIALS AND METHODS 
Polymorphonuclear leukocytes (neutrophils) were isolated 
from heparinized venous blood from healthy volunteers utihs- 
ing either a dextran/ficoll sedimentation procedure [lo] or 
Mono-Poly Resolving Medium (Flow Laboratories) as describ- 
ed in the manufacturer’s instructions. After purification, cells 
were suspended either in a Krebs/Hepes buffer containing 
(mM): 120 NaCI; 4.8 KCl; 1.2 KHzPOd; 1.3 Cat&; 1.2 MgS04; 
25 Hepes (pH 7.4) and 0.1% bovine serum albumin, or RPM1 
1640 medium (Flow Laboratories). Neutrophils (>98% purity) 
were counted using a Fuchs-Rosenthal haemocytometer slide 
and used within 5 h of preparation. 
2.1. Measurement of ~‘S]methionine incorporation 
Neutrophils were suspended in RPM1 1640 medium to 2-4 x 
10’ cells/ml at 37°C. To each incubation mixture, 60,&i/m] 
(final cont.) of [?S]methionine was added and neutrophils were 
maintained in suspension by gentle agitation. After a 10 min 
pre-incubation period, fMet-Leu-Phe, y-interferon or rGM- 
CSF were added (at the stated concentrations), whilst control 
suspensions contained no additions or else 0.01% DMSO (used 
as the solvent vehicle for fMet-Leu-Phe). After 60 min incuba- 
tion, portions were removed and proteins precipitated with 10% 
TCA (final cont.) containing 2% (w/v) casein hydrolysate for 
16 h at 4°C. Precipitated proteins were then filtered onto What- 
man GF/C filters, washed six times with 10% TCA and finally 
once with ethanol. The filters were then dried, mixed with 4 ml 
of Scintillation Cocktail T (BDH Chemicals) and counted using 
a Packard Scintillation Counter. 
2.2. Two-dimensional polyacrylamide gel electrophoresis 
Neutrophils were suspended in RPM1 1640 medium contain- 
ing 60pCi/ml [‘?S]methionine and incubated for 60 min at 
37°C. After this period proteins were precipitated with 10% 
TCA for 16 h at 4°C and then centrifuged at 11600 x g for 
5 min. The supernatants were discarded and the protein 
precipitates washed five times with 1 ml aliquots of ether (to 
remove traces of TCA). After the final wash and removal of 
supernatants, the pellets were warmed to 37°C to remove 
residual traces of ether. Protein precipitates were then analysed 
by two-dimensional gel electrophoresis employing a system 
utilizing isoelectric focusing (IEF) [l 11 for the first dimension: 
the second dimension employed a 13 % polyacrylamide gel con- 
taining SDS. After electrophoresis, gels were soaked in DMSO 
for 3 h (with 3 changes) prior to soaking in a PPO (2,5-diphenyl 
oxazole) solution in DMSO (20%, w/w, final cont.). After ex- 
tensive washing in double-distilled water, gels were dried and 
exposed to pre-flashed Fuji RX X-Ray film at -70°C for 2-3 
weeks. 
2.3. Reactive oxidant generation 
Suspensions of neutrophils (1-2 x lo6 cells/ml) were in- 
cubated with 10 mM luminol as described previously [12] and 
chemiluminescence was measured using an LKB Wallac 1250 
luminometer. Rates of Or production were measured as 
superoxide dismutase-inhibitable cytochrome c reduction [13]. 
3. RESULTS 
3.1. Effect of rGM-CSF and y-interferon on 
oxidant generation 
Neutrophil suspensions were incubated at 37°C 
for 15 min in the presence or absence of y- 
interferon (100 U/ml) or rGM-CSF (50 U/ml) and 
then stimulated by the addition of 1 PM (final 
cont.) fMet-Leu-Phe (suitable experiments howed 
that these concentrations of y-interferon and rGM- 
CSF produced maximal priming of oxidant pro- 
duction). Fig.1 shows that y-interferon pre- 
treatment resulted in a 2-fold increase in the total 
chemiluminescence generated after stimulation by 
fMet-Leu-Phe, whereas a greater enhancement 
(3-fold) was observed upon pre-treatment with 
rGM-CSF. Similar effects were observed when oxi- 
dant generation was measured using lucigenin- 
dependent chemiluminescence (data not shown). 
Similarly, y-interferon primed fMet-Leu-Phe 
stimulated Or secretion (fig.2), but again the prim- 
ing effect induced by rGM-CSF was greater. 
3.2. Effects of priming agents on rates of protein 
biosynthesis 
As rGM-CSF induced a similar effect to y- 
interferon on stimulated oxidant generation, we 
next examined its effects on protein biosynthesis. 
Thus, bloodstream neutrophils were incubated in 
RPM1 1640 medium supplemented with 60 ,&i/ml 
[35S]methionine, and after 60 min incubation at 
37°C radioactivity incorporated into TCA- 
precipitable material was measured. Control in- 
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Fig.1. Effect of rGM-CSF and -y-interferon on fMet-Leu-Phe 
chemiluminescence. Neutrophils were suspended in 
Krebs/Hepes buffer at lo6 cells/ml containing 10 PM luminol. 
After 15 min incubation at 37°C in the absence (i) or presence 
of 100 U/ml y-interferon (ii) or 50 U/ml rGM-CSF (iii), 
suspensions were stimulated by the addition of 1 pM (final 
cont.) fMet-Leu-Phe. Similar results were obtained in at least 
5 other separate experiments. 
cubations contained either no additions or 0.01% 
DMSO (used as a solvent vehicle for fMet-Leu- 
Phe) whereas primed suspensions contained either 
rGM-CSF (50 U/ml), y-interferon (100 U/ml) or 
fMet-Leu-Phe (0.1 PM). Compared to the low 
levels of [35S]methionine incorporated into control 
suspensions, all of the priming agents used resulted 
in a marked and reproducible stimulation of incor- 
poration (table 1). 
3.3. Two-dimensional 
electrophoresis 
polyacrylamide gel 
We have previously shown that the polypeptides 
synthesised after exposure of neutrophils to either 
0 I 2 3 4 
Time (min) 
Fig.2. Effect of priming agents on OF production. Neutrophils 
were suspended in Krebs/Hepes buffer containing 75 PM 
cytochrome cat 5 x 10’ cells/ml. Other experimental conditions 
were exactly as described for fig.1. 
fMet-Leu-Phe [3] or y-interferon [5] fall into one 
of two classes, namely one group whose rate of 
labelling changes very little (l-2-fold) and a se- 
cond whose rate of labelling increases lo-20-fold. 
We next examined, therefore, whether rGM-CSF 
induced similar changes in the polypeptide profiles 
of these cells. Bloodstream neutrophils were thus 
incubated in the presence or absence of rGM-CSF 
for 60 min and newly-labelled polypeptides were 
analysed by two-dimensional polyacrylamide gel 
electrophoresis. Fig.3 shows that in control 
suspensions a number of [35S]methionine-labelled 
polypeptides were observed, whereas in rGM-CSF- 
treated suspensions a greater number of labelled 
polypeptides were detected and the intensity of 
Table 1 
Stimulation of protein biosynthesis by some neutrophil priming 
agents 
Compound Concentration Increased rate of protein 
biosynthesis 
fMet-Leu-Phe 0.1 gM 3.6 f 1.7 (n = 9) 
y-Interferon 100 U/ml 3.2 k 1.4 (n = 9) 
rGM-CSF 50 U/ml 2.2 + 0.5 (n = 9) 
Neutrophils were suspended in RPM1 1640 medium 
supplemented with 60&i/ml [%]methionine at 2-4 x 10’ 
cells/ml. Suspensions contained no further additions (or 0.01% 
DMSO as solvent vehicle for fMet-Leu-Phe) or else were treated 
with the neutrophil priming agents at the concentrations 
indicated. After 60 min incubation at 37°C proteins were 
precipitated and incorporated radioactivity counted, as 
described in section 2. Values presented are means of the fold 
incorporation over control suspensions (with standard 
deviations). n, number of determinations 
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Fig.3. Two-dimensional polyacrylamide gel electrophoresis. Neutrophils were suspended at 2-4 x 10’ cells/ml in RPM1 1640 
containing 60 &i/ml [35S]methionine for 60 min in the absence (a) or presence (b) of 50 U/ml rGM-CSF. After this incubation 
radiolabelled polypeptides were precipitated and resolved by gel electrophoresis as described in section 2. 
labelling of some was greatly increased. The 
relative rates of labelling of twelve polypeptides 
were estimated by excising corresponding spots 
from both control and rGM-CSF-treated gels and 
measuring incorporated radioactivity by scintilla- 
tion counting. With six of these polypeptides the 
ratio of labelling (cpm incorporated into rGM-CSF 
treated i cpm incorporated into control) ranged 
from 0.7 to 2.0, whereas for the other six polypep- 
tides this ratio ranged from 3 .O to 11 .O. 
4. DISCUSSION 
The data presented in this report clearly 
demonstrate that in common with some other 
neutrophil priming agents [3-51, rGM-CSF can 
both prime the respiratory burst (figs 1,2) and ac- 
tivate de novo protein biosynthesis (table 1, fig.3) 
in mature, circulating neutrophils. Interestingly, 
analysis of [35S]methionine-labelled polypeptides 
on two-dimensional gels revealed two classes of 
proteins in rGM-CSF-treated cells. The first of 
these comprised polypeptides whose rate of label- 
ling increased little (if at all) after exposure to the 
colony-stimulating factor, whereas the second 
class comprised polypeptides whose rate of label- 
ling was markedly up-regulated uring priming. It 
thus appears that in common with our previous 
observations [3,5], the priming treatment induces a 
selective up-regulation of gene expression. 
GM-CSF is of considerable clinical interest as it 
has the ability to increase both the number (via its 
effects on myelomonocytic cell proliferation) and 
activity (via its priming ability) of circulating 
neutrophils. In vitro it has been shown to enhance 
stimulated reactive oxidant production [ 14,151 and 
alters both the number and affinity of some 
neutrophil receptors [16]. It is thus of therapeutic 
interest for the treatment of patients with 
granulocyte defects or granulocytopenias induced 
by disease or myelosuppressive therapy, and who 
inevitably are susceptible to microbial infections. 
Clinical trials in patients with granulocytopenias, 
immune deficiencies or carcinomas have shown 
that as well as increasing the numbers of cir- 
culating granulocytes, their functional charac- 
teristics resemble those observed during priming in 
yitro [ 17-221. 
The discovery that, in common with some other 
priming agents [3,5], rGM-CSF stimulates de novo 
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protein biosynthesis in mature, circulating 
neutrophils adds further evidence to the now grow- 
ing literature that these cells do indeed possess a 
significant capacity for active macromolecular 
biosynthesis [23]. Further work is clearly necessary 
to identify these up-regulated proteins and to 
establish their biological role during an inflam- 
matory response. It is of considerable interest to 
note that the GM-CSF treatment has been shown 
to activate the transcription of c-fos [24], 
interleukin-1 [25] and G- and M-CSF [26]. Our 
data show that the expression of considerably 
more cellular components is up-regulated during 
cytokine treatment. The somewhat naive view that 
mature neutrophils are biosynthetically incompe- 
tent must now be revised: these cells respond to in- 
flammatory signals to generate their own set of 
pro- (and perhaps anti-)inflammatory signals 
which can serve to augment the recruitment, in- 
filtration and proliferation of granulocytes, and 
hence elaborate the immune response to infection. 
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